DOSAGE INDEX / SINGLE
PNC-27
Research, reported schedules and supply planning.
Understand PNC-27 membrane-targeting research, leukemia models and FDA product warnings without mistaking experiments for an established cancer treatment.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 100–500 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
This is an experimental source claim, not an established cancer treatment. It does not justify delaying diagnosis or standard oncology care.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 30 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- PNC-27 is an engineered peptide investigated in laboratory cancer research, including membrane interactions and leukemia models. Those studies do not establish a proven treatment for cancer in people. FDA has warned about unapproved PNC-27 products promoted with cancer-treatment claims. [1] [2]
- The 2010 report describes PNC-27 as a p53-derived HDM2-binding segment linked to a membrane-penetrating sequence. Investigators placed different fluorescent labels at its two ends and compared breast-cancer cells with an untransformed breast epithelial line. The combined signal remained associated with cancer-cell membranes during cell breakdown, supporting activity of the intact peptide. The comparison cells remained viable under the tested conditions. [1]
- A 2019 study investigated membrane HDM2 in acute myeloid leukemia, including leukemia-stem-cell-enriched populations. PNC-27 was associated with membrane damage and killing of leukemia cells. Transplant experiments using human and murine leukemia models supported activity against bulk disease and leukemia-initiating populations, while normal hematopoietic stem-cell activity was spared in the reported mouse transplantation tests. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 11 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original cell study
- FDA cancer-product resource
- Original AML study
- Journal of Biomedical Science (2017)Further reading · Listed in reference bibliography.
- International Journal of Cancer (2006)General guidance · Listed in reference bibliography.
- BMC Cancer (2008)Further reading · Listed in reference bibliography.
- PubMed (2012)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- National Hemophilia Foundation (2021)Further reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.